Jonathan Moggs


Jonathan Moggs is Director & Head of Molecular Toxicology (Investigative Toxicology, Preclinical Safety, Translational Sciences, Novartis Institutes for Biomedical Research) and has over 10 years of experience in preclinical safety assessment and drug development within both Agrochemical and Pharmaceutical industries, with an emphasis on investigating mechanisms of toxicity at molecular, biochemical and cellular levels. He is project leader of the EC Innovative Medicines Initiative MARCAR Non-Genotoxic Carcinogenesis Program. Prior to joining Novartis, Jonathan was Head of Investigative Toxicology at Syngenta Central Toxicology Laboratory where he led the application of Genomic, Functional Proteomic and Epigenomic sciences within safety assessment. He was also recipient of the British Toxicology Society Young Investigator Award in 2005. His postdoctoral research (EMBO and EU TMR fellowships) focused on interrelationships between Chromatin Dynamics, Gene Expression and DNA Repair (Institut Curie, Paris, France). He has a D.Phil. in Biochemistry (University of Sussex & Imperial Cancer Research Fund, United Kingdom) and a Bachelor degree in Biochemistry (Oxford University, United Kingdom).

Role in the Project

MARCAR Coordinator. Leader of MARCAR Workpackage 1 focusing on the application of integrated genome-wide molecular profiling (DNA methylation+ chromatin modifications+ +mRNA+microRNA) to provide mechanistic insight and identify novel early biomarkers for non-genotoxic carcinogenesis.